G‐Quadruplex RNA Based PROTAC Enables Targeted Degradation of RNA Binding Protein FMRP for Tumor Immunotherapy
Angewandte Chemie International Edition · 18.11.2024 · 63 (47)
DOI: 10.1002/anie.202402715 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 14.10.2024. Verfasst von Ruixi Peng und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, 410082, Changsha, P. R. …. Hauptthemen laut MEDLINE: G-Quadruplexes, Fragile X Messenger Ribonucleoprotein 1, Immunotherapy, Proteolysis. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Program of Hunan Province.
Abstract (Originalsprache)
Fragile X mental retardation protein (FMRP), an RNA binding protein (RBP), is aberrantly hyper‐expressed in human tumors and plays an essential role in tumor invasion, metastasis and immune evasion. However, there is no small‐molecule inhibitor for FMRP so far. In this study, we developed the first FMRP‐targeting degrader based on PROteolysis TArgeting Chimera (PROTAC) technology and constructed a heterobifunctional PROTAC through linking a FMRP‐targeting G‐quadruplex RNA (sc1) to a von Hippel‐Lindau (VHL)‐targeting ligand peptide (named as sc1‐VHLL). Sc1‐VHLL specifically degraded endogenous FMRP via ubiquitination pathway in both mouse and human cancer cells. The FMRP degradation significantly changed the secretion pattern of cancer cells, resulting in higher expression of pro‐inflammatory cytokine and smaller amounts of immunomodulatory contents. Furthermore, sc1‐VHLL, when encapsulated into ionizable liposome nanoparticles (LNP), efficiently targeted tumor site and degraded FMRP in cancer cells. In CT26 tumor‐bearing mouse model, FMRP degradation within tumors substantially promoted the infiltration of lymphocytes and CD8 T cells and reduced the proportion of T reg cells, reshaping the proinflammatory tumor microenvironment and accordingly transforming cold tumor into hot tumor. When combined with immune checkpoint blockade (ICB) therapy, sc1‐VHLL based treatment remarkably inhibited the tumor growth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, 410082, Changsha, P. R. China.
ORCID-Profile: Ruixi Peng, Xia Chu
Förderung
- National Natural Science Foundation of China
- Science and Technology Program of Hunan Province
Zitieren
APA
Peng, R., Huang, Q., Wang, L., Qiao, G., Huang, X., Jiang, J., & Chu, X. (2024). G‐Quadruplex RNA Based PROTAC Enables Targeted Degradation of RNA Binding Protein FMRP for Tumor Immunotherapy. Angewandte Chemie International Edition, 63(47). https://doi.org/10.1002/anie.202402715
Vancouver
Peng R, Huang Q, Wang L, Qiao G, Huang X, Jiang J, et al. G‐Quadruplex RNA Based PROTAC Enables Targeted Degradation of RNA Binding Protein FMRP for Tumor Immunotherapy. Angewandte Chemie International Edition. 2024;63(47). doi:10.1002/anie.202402715
BibTeX
@article{Peng2024,
author = {Peng, Ruixi and Huang, Qian and Wang, Li and Qiao, Gongxi and Huang, Xiangrong and Jiang, Jianhui and Chu, Xia},
title = {G‐Quadruplex RNA Based PROTAC Enables Targeted Degradation of RNA Binding Protein FMRP for Tumor Immunotherapy},
journal = {Angewandte Chemie International Edition},
year = {2024},
volume = {63},
number = {47},
doi = {10.1002/anie.202402715}
}
EUVIMED